label: IWG-MRT Myelodysplastic Syndrome Major Hematologic Improvement-Erythroid Response in High Transfusion Burden
label_lc: iwg-mrt myelodysplastic syndrome major hematologic improvement-erythroid response in high transfusion burden
description: "Major hematologic improvement-erythroid response in high transfusion burden patients corresponds to transfusion independence, defined by the absence of any transfusions over a period of a minimum of 8 weeks within an observation period of 16 to 24 weeks with the same transfusion policy (defined in \"1.2.4. Transfusion policy\") compared with 16 weeks prior to treatment. Only a response duration of at least 16 weeks, however, is considered clinically meaningful. (Adapted from Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials; Blood 2019 133: 1020-1030)"